Abstract
Purpose of review: This review summarises recent developments in monitoring and immunosuppressive management in kidney transplantation. Recent findings: Long-term kidney allograft outcomes have not changed substantially mainly as a result of acute and chronic antibody-mediated rejection.
Several groups have recently attempted to determine peripheral molecular fingerprints of ongoing rejection. But while this research is promising, it is not generalised for further spreading among different cohorts.
Measurements of donor-derived cell-free DNA levels in recent studies have revealed better predictive values for antibody-mediated rejection. The Molecular Microscope Diagnostic System for assessing kidney graft biopsies has been gradually introduced within clinical practice, especially in complicated cases aimed at improving histological diagnostics.
Molecular studies on accommodation in ABO-incompatible transplantation have shown increased complement regulation and lower expression of epithelial transporters and class 1 metallothioneins. Additionally, in clinical studies of sensitised patients, imlifidase has been shown to enable transplantation across significant immunological barriers, while the co-stimulation blockade has been tested to prevent donor specific antibodies development.
In low-risk patients, everolimus/tacrolimus-based regimens have also proven their antiviral effects in large clinical trials. Summary: Recent developments in non-invasive monitoring have paved the way for the introduction of future larger clinical trials with multiple patient cohorts.